Matthew Jenner
0000-0003-0216-7464
Publication & Citation Trends
Publications
0 total
Challenging the concept of functional high-risk myeloma through transcriptional and genetic profiling
Cited by 4
Semantic Scholar
Final Analysis of the Randomised UK MRA Myeloma XI+ Trial Examining Krdc (carfilzomib, lenalidomide, dexamethasone and cyclophosphamide) As Induction Therapy for Newly Diagnosed Multiple Myeloma Patients
Cited by 0
Semantic Scholar
Efficacy and Safety of Daratumumab in Intermediate/High-risk Smoldering Multiple Myeloma: Final Analysis of CENTAURUS. OA
Cited by 15
Semantic Scholar
Extended Intensified Consolidation and Maintenance Improve Ultra High-Risk Multiple Myeloma Patient Outcome - Long-Term Follow-up of the Ukmra Optimum/Muknine Trial
Cited by 2
Semantic Scholar
A Novel Segmentation-Based Purity-Informed Approach Accurately Detects Total Copy Number and Its Subclonal Fraction in Myeloma Targeted Panel Sequencing Data
Cited by 0
Semantic Scholar
Belantamab Mafodotin Plus Cyclophosphamide and Dexamethasone for Patients with Relapsed or Refractory Multiple Myeloma: Interim Results from the UK Myeloma Research Alliance Prommise Clinical Trial
Cited by 1
Semantic Scholar
Impact of minimal residual disease (MRD) in salvage autologous stem cell transplantation for relapsed myeloma: results from the NCRI Myeloma X (intensive) trial
Cited by 0
Semantic Scholar
Optimising the Duration of Therapy for Newly Diagnosed Transplant Ineligible Patients - Analysis of Long Term Follow up Data from the UK MRA Myeloma XI Trial
Cited by 1
Semantic Scholar
Research Topics
Multiple Myeloma Research and Treatments
(175)
Protein Degradation and Inhibitors
(81)
Cancer Treatment and Pharmacology
(56)
Peptidase Inhibition and Analysis
(31)
Acute Myeloid Leukemia Research
(16)
Affiliations
University of Leeds
University Hospitals Birmingham NHS Foundation Trust
Royal Marsden NHS Foundation Trust
Harvard University
Institute of Cancer Research